OraTest in Combination With Visual Examination and Visual Examination Alone
This study has been terminated.
(Study terminated early as per request by sponsor, Zila Biotechnology, Inc.)
Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Zila Biotechnology
Information provided by:
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00537199
First received: September 26, 2007
Last updated: December 11, 2009
Last verified: December 2009
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Primary Objectives:
- To assess the ratio in sensitivities of OraTest® in combination with visual examination versus visual examination alone in the detection of serious pathology defined as severe dysplasia, CIS, or cancer of the O/OP cavity in patients who are at high risk for squamous cell carcinoma, carcinoma in situ, or severe dysplasia of the oral/oropharyngeal (O/OP) cavity due to their age and lifestyle risk factors.
- To estimate the adjusted specificity of OraTest® in combination with visual examination in the detection of severe dysplasia, CIS, or cancer of the O/OP cavity.
Secondary Objectives:
- To assess the ratio of sensitivity of OraTest® in combination with visual examination versus visual examination alone in the detection of certain chromosomal abnormalities (17p chromosomal deletions, or both 3p and 9p chromosomal deletions), severe dysplasia, CIS, or cancer of the O/OP cavity in patients who are at high risk for squamous cell carcinoma, carcinoma in situ, or severe dysplasia of the oral/oropharyngeal (O/OP) cavity due to their age and lifestyle risk factors.
- To obtain the adjusted specificity of OraTest® in combination with visual examination in the detection of certain chromosomal abnormalities (17p chromosomal deletions, or both 3p and 9p chromosomal deletions), severe dysplasia, CIS or cancer of the O/OP cavity.
- To evaluate the chromosomal status of the positively staining lesions with respect to 3p, 9p, or 17p deletions.
- To carry out gene expression studies on biopsies and map these onto an analysis of the widespread chromosomal imbalances in stain-positive and stain-negative lesions.
- To evaluate the quantitative and qualitative toxicities, as well as other safety parameters, of tolonium chloride 5 mg/mL (OraTest®).
| Condition | Intervention | Phase |
|---|---|---|
|
Head and Neck Cancer Oropharynx Cancer |
Other: Visual Examination Drug: OraTest |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Evaluation of OraTest in Combination With Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer: Phase III Clinical Trial Comparing the Sensitivity and Assessing the Specificity of OraTest in Combination With Visual Examination and Visual Examination Alone in Patients at High Risk as Defined by Age and Lifestyle Factors (ZIL-401) |
Resource links provided by NLM:
Further study details as provided by M.D. Anderson Cancer Center:
Primary Outcome Measures:
- Ratio of Sensitivity of OraTest + Visual Exam Versus Sensitivity of Visual Exam Alone [ Time Frame: Two (2) scheduled visits for visual examination. ] [ Designated as safety issue: No ]
| Enrollment: | 1 |
| Study Start Date: | February 2007 |
| Study Completion Date: | December 2008 |
| Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
OraTest + Visual Exam
OraTest dye
|
Other: Visual Examination
Two (2) scheduled visits for visual examination of mouth for abnormal lesions and glands in the neck.
Drug: OraTest
Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
Other Names:
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 45 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- High risk of oral cancer as defined by a twenty-pack/year cigarette smoking history or equivalent and is either a current smoker or has quit smoking within the last 24 months. Twenty-pack/year equivalent is defined as ½ pack/day for 40 years, or one pack/day for 20 years, or 2 packs/day for 10 years, or 4 packs/day for 5 years. AND/OR;
- Ten-year history of twenty orally-consumed alcohol units/week and is either a current drinker or has quit drinking within the last 24 months. Twenty orally-consumed alcohol units/week is defined as the equivalent of twenty - 1 ounce shots of whisky or spirits/week (20 ounces = 600 mL), or twenty - 3 ounce glasses of wine/week (60 ounces = 1800 mL), or twenty - 12 ounce glasses of beer/week (240 ounces = 7200 mL);
- Male or female, at least 45 years of age;
- Written informed consent.
- Females of childbearing potential may be enrolled following a negative urine pregnancy test performed at the SE visit. Abstinence will be considered an acceptable form of birth control.
Exclusion Criteria:
- History of oral cancer, surgery or biopsy for suspected oral neoplasm;
- History of recent oral surgery, periodontal treatment, or oral trauma (<14 days) or current orthodonture (e.g., braces);
- Known hypersensitivity to study drug or its analogs;
- Active and uncontrolled infection or any other severe concurrent disease that in the judgment of the investigator would make the patient inappropriate for entry into this study;
- Psychiatric disorders which would interfere with informed consent or follow-up;
- Use of any investigational agent within previous 30 days;
- Female that is lactating or demonstrating positive pregnancy test;
- Patients in whom betel nut use/abuse has been reported within the past 5 years;
- Patients currently taking medication containing prohibited dyes.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00537199
Locations
| United States, Texas | |
| U.T.M.D. Anderson Cancer Center | |
| Houston, Texas, United States, 77030 | |
Sponsors and Collaborators
M.D. Anderson Cancer Center
Zila Biotechnology
Investigators
| Principal Investigator: | Mark Chambers, DMD | M.D. Anderson Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | Mark S. Chambers, MD / Professor, U.T. M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00537199 History of Changes |
| Other Study ID Numbers: | 2005-1008 |
| Study First Received: | September 26, 2007 |
| Results First Received: | December 11, 2009 |
| Last Updated: | December 11, 2009 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by M.D. Anderson Cancer Center:
|
Head And Neck Oropharynx Oral Cancer OraTest |
OraTest Dye Rinse Staining Procedure Visual Examination |
Additional relevant MeSH terms:
|
Head and Neck Neoplasms Mouth Neoplasms Oropharyngeal Neoplasms Neoplasms by Site Neoplasms Mouth Diseases |
Stomatognathic Diseases Pharyngeal Neoplasms Otorhinolaryngologic Neoplasms Pharyngeal Diseases Otorhinolaryngologic Diseases |
ClinicalTrials.gov processed this record on May 22, 2013